Boston Millennia Partners

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse™ a Local Anesthetic Reversal Agent
Novalar Pharmaceuticals, Inc. announced the publication of three clinical trials on the use of OraVerse (phentolamine mesylate) injection as a local dental anesthetic reversal agent in the August 2008 issue of the Journal of the American Dental Association (JADA).

Learn More >

PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results PAREXEL reports record quarterly and Fiscal Year service revenue grows approximately 33% and 30%, respectively, operating margin of 9.9% for the quarter and record backlog of over $2 billion; net book-to-burn ratio of 1.56 for the quarter Learn More >
< Previous	Next >

Financing Facility May Provide EPIX Up To $50 Million of Capital EPIX Pharmaceuticals, Inc. announced that it has entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group. Learn More >
< Previous	Next >

New Hope for Alzheimer's Patients For Alzheimer's victims, help could be on it way. A new generation of drugs could not only alleviate symptons, but could stop progression of the devastating disease. Learn More >
< Previous	Next >

CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day CombinatoRx, Incorporated (provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA. Learn More >
< Previous	Next >

PHT's Valdo Arnera, MD, Named to PharmaVOICE 100 Most Inspiring People in Life Sciences PHT Corporation announced that its European General Manager, Valdo Arnera, MD, is one of PharmaVOICE magazine’s 100 most inspiring people in life sciences. Learn More >
< Previous	Next >

ClinPhone Shareholders Approve Acquisition by PAREXEL PAREXEL International Corporation provided an update with regard to the previously announced proposal whereby an indirect wholly owned subsidiary of PAREXEL will acquire the entire issued and to be issued ordinary share capital of ClinPhone plc. Learn More >
< Previous	Next >

Collegium Pharmaceutical Announces U.S. Patent Issued Covering its DETERx™ Abuse Deterrent Sustained Release Technology Collegium Pharmaceutical, Inc. announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper resistant, abuse-deterrent formulation platform. Learn More >
< Previous	Next >

Collegium Pharmaceutical Announces Completion of Series D Financing Collegium Pharmaceutical, Inc., announced today that it has closed a $20 million Series D equity financing. Learn More >
< Previous	Next >

Arthrosurface Receives CE Mark Approval for Uni Knee Resurfacing System Arthrosurface, Inc. announced that it has received the CE Mark approval for its UniCAP™ Unicondylar resurfacing system. With this approval, the company is poised to move into the fast growing European market of partial knee replacements. Learn More >
< Previous